A new AI-powered screening system by AEYE Health, a company co-founded by Zack Dvey-Aharon, reduces diagnosis of diabetic retinopathy to a minute, via a handheld camera and a single image of each retina — all without the need for a physician in the loop. Read more...
Read MoreYaron Segal has, like many thousands of enterprising Israelis, identified a problem. And like so many in a country driven by technological innovation, he’s established a startup to find a solution. But he’s not so interested in the payday “exit” that attracts most entrepreneurs in the Startup Nation. His ultimate goal is to find a treatment for his son Lear, born 23 years ago born with familial dysautonomia, a rare and progressive genetic neurological disorder. Read more on...
Read MorePlenty Unlimited Inc. has driven many advancements in indoor farming over the past decade in its research and development (R&D) center in Laramie, Wyo., leveraging its proprietary R&D technology platform. Today it’s one of the top plant science research centers in the world, attracting expert scientists from all over the world as well as leveraging talent from the nearby University of Wyoming. After receiving the largest economic development grant ever given by the State of Wyoming, Plenty is expanding its R&D footprint and building the world’s largest vertical farming research center in Laramie with the support of the Wyoming Business Council, Laramie Chamber Business Alliance and City of Laramie. Read...
Read MoreCharles River Laboratories International, Inc. (NYSE: CRL) and Insightec, a global healthcare company dedicated to using focused ultrasound to transform patient care, today announced the launch of a five-year strategic collaboration to provide Charles River’s clients access to a comprehensive global service and technology platform for the application of focused ultrasound (FUS) for drug discovery and preclinical development of therapeutics in neuroscience. Insightec’s novel low-frequency ultrasound platform non-invasively disrupts the blood brain barrier, enabling drugs to be delivered to targeted brain areas. The procedure has generated positive clinical evidence across several neurological diseases, including Parkinson’s disease, Alzheimer’s disease, and oncology indications, and holds promise for increasing efficacy of neurological drugs, to impact better health and outcomes for patients in the future. Read...
Read MoreIf we’ve learned anything from the Age of AI, it’s that the industry is grappling with significant power challenges. These challenges are both literal—as in finding ways to meet the voracious energy demands that AI data centers require—and figurative—as in the concentration of AI wealth in a few hands based on narrow commercial interests rather than broader societal benefits. Read...
Read More
